drugset / Trial / NCT05411757
IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver Cancer
Phase 0
Unknown
12 enrolled
Shandong Public Health Clinical Center
Imbioray (Hangzhou) Biomedicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, nonrandomized investigator-initiated clinical trial to evaluate the safety, tolerability, and efficacy of IBR900 cell injection in combination with Lenvatinib or bevacizumab in subjects with advanced primary liver cancer.
Timeline
- Start
- 2022-06-30
- Primary completion
- 2023-06-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | IBR900 | Cell therapy | 4e+09 cells | — |
| Subject | Lenvatinib | Small molecule | 8 mg | — |
| Subject | Lenvatinib | Small molecule | 12 mg | — |